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Abstract
Variations in the TP53 gene have been suggested to play a role in many cancers, including
breast. We previously observed an association between TP53 haplotypes based on four
polymorphisms (rs17878362, rs1042522, rs12947788, and rs17884306) and the risk of
colorectal and pancreatic cancer. Based on these results, in the present study, we have
investigated the same polymorphisms and their haplotypes in 705 breast cancer cases and
611 healthy controls in relation to the disease risk, histopathological features of the tumor
and clinical outcomes. In comparison to the most common haplotype A1-G-C-G, all the
other identified haplotypes were globally associated with a significantly decreased breast
cancer risk (P = 0.006). In particular, the A2-G-C-G haplotype was associated with a marked
decreased risk of breast cancer when compared with the common haplotype (P = 0.0001).
Moreover, rs1042522 in patients carrying the GC genotype and receiving only the anthracy-
cline-based chemotherapy was associated with both overall and disease-free survival
(recessive model for overall survival HR = 0.30 95% CI 0.11–0.80, P = 0.02 and for disease-
free survival HR = 0.42 95% CI 0.21–0.84, P = 0.01). Present results suggest common
genetic features in the susceptibility to breast and gastrointestinal cancers in respect to
TP53 variations. In fact, similar haplotype distributions were observed for breast, colorectal,
and pancreatic patients in associations with cancer risk. Rs1042522 polymorphism (even
after applying the Dunn-Bonferroni correction for multiple testing) appears to be an indepen-
dent prognostic marker in breast cancer patients.
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Introduction
Breast cancer (BC) is the third most common tumor worldwide (and the most frequent in
women), representing 9% of the global cancer burden. Epidemiologic studies have suggested a
number of risk factors including personal, family, and gynecological history, as well as an inter-
play between genetic and environmental factors [1]. Mutations in the rare high penetrance BC
predisposing genes BRCA1 and BRCA2 account for 16–25% of the inherited component of this
cancer [2]. To date, GWAS conducted for BC have identified more than 80 breast cancer sus-
ceptibility loci (all summarized in [3]). Although, several candidate gene association studies for
BC have been conducted during the last decade [4–10], many of them were underpowered due
to small sample size, resulting in inconsistent and not reproducible findings [11,12]. To date,
only one polymorphism located in the coding region of CASP8 (rs1045485) has shown promise
as a breast cancer predisposition risk factor [3,13].
The prognosis of breast carcinoma is mostly influenced by tumor stage, grade, overexpres-
sion of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2), and hor-
monal receptors. These factors are routinely considered in selecting the treatment regimen for
each individual [14]. Anthracycline combination chemotherapies are the most effective and
widely used regimens for the treatment of BC [15]. Radiotherapy, on the other hand, improves
BC survival by reducing the risk of local recurrence, whereas it has no direct impact on metas-
tasis [16]. Besides, still novel biomarkers are needed to identify individuals who would benefit
most from a given treatment regimen. Such markers might arise from inherited genetic varia-
tion, which—apart from BC susceptibility—may affect disease progression, response to treat-
ment and outcome [17].
p53 protein (encoded by TP53 gene) is a key player in stress responses that preserve geno-
mic stability responding to a variety of insults including DNA damage, hypoxia, metabolite
stress and oncogene activation [18]. In addition, p53 interacts with numerous cellular proteins
including those controlling the programmed cell death. This tumor suppressor gene is fre-
quently mutated in various solid tumors, including colorectum, pancreas, and breast. These
mutations result in the absence or dysfunction of the corresponding protein [19]. TP53 is also
polymorphic: so far, 547 single nucleotide polymorphisms (SNPs) have been identified (http://
genecards.org). Owing to the importance of p53 in tumor suppression, SNPs that may alter its
function might affect not only cancer risk but also its progression and/or response to the treat-
ment [18]. TP53 rs1042522 is one of the most commonly investigated variants in cancer genetic
epidemiology. However, two recent reviews [20,21] suggested that this polymorphism is
unlikely to be a risk factor for BC. Instead, a recent meta-analysis on rs17878362 (PIN3,
Ins11951_11966, allele A2 carries the 16-bp insertion within intron 3) has found an increased
risk of BC in A2A2 carriers [22]. Previous studies have suggested rs1042522 as a prognostic
marker for BC [23–26]. On the contrary, the role of TP53 haplotypes has not yet been fully
investigated for BC susceptibility and its clinical outcome.
Previously, we have studied the role of four TP53 polymorphisms on colorectal cancer
(CRC) and pancreatic cancer risk. In both studies, we have observed a consistent differential
distribution of the major haplotypes built on the four variants between cases and controls,
suggesting that prevalent haplotypes within the TP53 gene may modulate both CRC and pan-
creatic cancer risk [27,28]. In the present investigation, we evaluated the association of the
same variations within TP53 gene and resulting haplotypes (loci in the order: rs17878362,
rs1042522, rs12947788, and rs17884306) with the risk of BC in a hospital-based case-control
study from the Czech Republic. In this country, around 6,000 women every year are diagnosed
with BC, and about 2,000 women die because of this cancer (incidence rank: 30th worldwide
and 18th in Europe; mortality rates rank: 117th worldwide and 36th in Europe; www.mamo.cz).
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In a set of the BC patients with complete follow-up, we also investigated the prognostic rele-
vance of TP53 gene variability.
Material and Methods
Study population
The study population comprised 705 BC patients and 611 healthy controls. Blood samples
were obtained from women with incident BC consecutively diagnosed in three hospitals in
Prague between February 2002 and December 2010. Sample collection from patients was
described elsewhere [29–31]. All subjects were informed and provided written consent to par-
ticipate in the study and to use their biological samples for genetic analyses, according to the
Helsinki declaration. The design of the study was approved by the Ethical Committee of the
Institute of Experimental Medicine, Prague, Czech Republic.
The control group consisted of healthy women whose information were previously
described in other association studies [27,32–34]. Two control groups were included in the
study. The first group consisted of 268 hospital-based individuals admitted to gastroenterologi-
cal departments that had negative colonoscopy results for malignancy or idiopathic bowel dis-
eases. The reasons for undergoing the colonoscopy were: (i) positive fecal occult blood test, (ii)
hemorrhoids, (iii) abdominal pain of unknown origin, and (iv) macroscopic bleeding. They did
not have any malignancy at the time of the sampling. The second group of controls consisted
of 343 healthy blood donor volunteers collected from a blood donor center in Prague. All indi-
viduals were subjected to standard examinations to verify the health status for blood donation
and were cancer-free at the time of the sampling.
The following data on patients were retrieved from medical records: date of cancer diagno-
sis, age, menopausal status, family history of cancer (number of relatives affected by BC, ovar-
ian cancer or other malignant diseases), tumor size, UICC (International Union Against
Cancer) tumor-node-metastasis (TNM) system classification, histological type and grade of
tumor, expression of estrogen receptor (ER), progesterone receptor (PR) and ERBB2, expres-
sion of the Ki-67 protein, chemotherapy and hormonal regimen. ERBB2 status was defined as
positive in samples with an immunohistochemical score of 2+ or 3+ [35]. Due to different
treatment of patients with metastasis, those women with metastasis were excluded from the
analysis.
For all cases, detailed information on radiotherapy, first line chemotherapy, and hormonal
therapy was available. Patients were treated with chemotherapy regimens containing 5-fluoro-
uracil, anthracycline, cyclophosphamide, and/or taxanes (for all treatments see S1 File). Infor-
mation about distant metastasis, relapse and date of death was also collected, with a follow-up
until December 31, 2013. In this study, the outcome variables measured were overall survival
(OS) and disease-free survival (DFS). The same variables were also investigated after stratifica-
tion according to anthracycline-, taxane-based chemotherapy, or hormonal-based therapy,
Selection of polymorphisms
The TP53 SNPs analysed were the same as those previously investigated for CRC [27] and pan-
creatic cancer [28] studies and represent part of the genetic variation in TP53 gene with
MAF5%. In particular, three tag SNPs were selected (rs1042522:G>C (Ex4+119 G>C,
Arg72Pro), rs12947788:C>T (IVS7+72 C>T) and rs17884306:G>A (Ex11-363 G>A)). In
the study, we also included the 16 bp insertion/deletion polymorphism within the intron
3 (rs17878362:A1>.A2, PIN3, Ins11951_11966, in which the A2 allele carries the 16 bp inser-
tion within the intron 3).
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SNP Genotyping
Genomic DNA was isolated from peripheral blood lymphocytes using standard procedures as
described in [36]. DNA samples from cases and controls were randomly placed on plates
where an equal number of cases and controls were run simultaneously. Genotyping of the
selected SNPs was carried out by using the KASPar chemistry of LGC Genomics (http://www.
lgcgenomics.com/genotyping/kasp-genotyping-reagents/kasp-technical-resources/), as
described in [37]. Duplicate samples (5%) and non-template controls in each plate were used
as quality control tests.
Rs17878362 in TP53 gene was genotyped by PCR-RFLP as previously described in [27] and
[28].
Statistical analyses
Chi-square test (1 degree of freedom), with a type-I error threshold set at α = 0.05, was used to
verify whether the genotypes were in Hardy-Weinberg equilibrium in controls. The haplotype
frequencies in cases and controls were estimated with the SAS/Genetics software module (SAS
Institute, Cary, NC, USA). The analysis was carried out to examine the phase of TP53 SNPs
using the expectation–maximization algorithm to generate maximum likelihood estimates of
haplotype frequencies.
The association between SNPs and BC risk was calculated by estimating the odds ratios
(ORs) and their 95% confidence intervals (CI) adjusted for age. For all SNPs, the co-dominant,
the dominant or the recessive models were calculated.
OS was defined as the time from the surgery to the date of death or the date of the end of
the study (December 31, 2013). DFS was defined as the time from surgery/end of therapy to
the occurrence of distant metastasis, local recurrence or death, whichever came first. The rela-
tive risk of death and recurrence was estimated as hazard ratio (HR) using Univariate Cox
regression, Multivariate Cox regression for significant results and Long-rank test. The survival
curves for overall and disease-free survival were derived by the Kaplan–Meier method. Multi-
variate survival analyses were adjusted for age and therapy. Statistical analyses were performed
using SAS software (SAS Institute, Cary, NC, USA).
Results
Case-control study
The study included 705 cases and 611 controls (detailed information in S1 File). The median
age (range) of patients at diagnosis was 59 (65–92) years while the median age of controls at
recruitment was 49 (57–85) years. There was a statistically significant difference in the age dis-
tribution between BC patients and controls (P<0.0001). Due to differences in age among cases
and controls, we have considered this factor as a confounding variable and used in our analysis
adjusting OR for it.
The distribution of genotypes within the four selected TP53 SNPs in controls was in agree-
ment with the Hardy-Weinberg equilibrium (Table 1). No significant differences were found
among cases and controls in the genotype frequencies for any of the polymorphisms when ana-
lyzed individually (Table 1). Rs17884306 resulted monomorphic (only GG genotype in all BC
subjects). Additionally, no clinicopathological parameters were associated with the risk of BC
after both univariate and multivariate analysis.
In the present study, the two most frequent haplotypes A1-G-C-G and A2-C-C-G comprised
the 83% of cases and only the 77% of controls. The A2-G-C-G haplotype was associated with a
significantly decreased risk of BC when compared with the reference haplotype A1-G-C-G,
TP53 Polymorphism and Breast Cancer Risk
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comprising only the common alleles (OR = 0.36, 95%CI 0.21–0.61, P = 0.0001; Table 2). When
the reference haplotype A1-G-C-G was compared to all other haplotypes, it resulted in associa-
tion with an increased BC risk (OR = 1.29, 95%CI 1.08–1.54, P = 0.006).
During the follow-up of BC cases, overall 77 patients died, with 39 of them due to cancer
progression. In addition, 78 subjects had recurrence (S1 File). Forty four patients were not
retrievable during follow-up, therefore, they were excluded from the analysis. The median OS
and DFS for the studied population were 54.3 and 52.2 months, respectively.
One hundred forty-four (20.4%) patients received neoadjuvant chemotherapy before sur-
gery. Concerning the adjuvant chemotherapy, 192 (51.9%) patients were administered with
antracyclines, 93 (25.1%) with taxanes, 34 (9.2%) with both agents in combination and 44
(11.9%) with others agents as first-line postoperative therapy (for more detail see S1 File).
Two hundred ninety-one (41.3%) subjects did not receive any adjuvant chemotherapy after
surgery, while 218 (30.9%) women received the hormonal therapy as a first line postoperative
therapy instead of adjuvant therapy. Finally, 318 (45.1%) patients were administrated with
both adjuvant and hormonal therapy, comprising mainly tamoxifen or inhibitors of aroma-
tases. Patients not receiving any hormonal therapy or radiotherapy or with advanced age (>60
years) resulted to have a shorter OS (log-rank P = 0.04; P = 0.006 and P = 0.01, respectively)
Table 1. Genotype distribution of investigated TP53 polymorphisms in BC patients and controls.
Genotypes Controlsa Casesa ORb 95% CI P HWEc
(n = 611) (n = 705) Χ2, P
rs17878362d 0.01, 0.99
A1A1 421 474 REF
A1A2 172 164 0.88 0.67–1.16 0.36
A2A2 18 24 1.13 0.57–2.24 0.71
A1A2+ A2 A2 190 188 0.91 0.70–1.18 0.46
rs1042522 0.35, 0.84
GG 301 370 REF
GC 260 275 0.89 0.70–1.14 0.35
CC 50 55 0.93 0.61–1.43 0.74
GC+CC 310 330 0.90 0.71–1.14 0.37
rs12947788 0.24, 0.89
CC 530 594 REF
CT 78 102 1.26 0.90–1.77 0.19
TT 2 5 1.60 0.30–8.53 0.58
CT+ TT 80 107 1.27 0.91–1.77 0.16
rs17884306 0.48, 0.79
GG 540 702
GA 66 0 - - -
AA 1 0 - - -
GA+AA 67 0 - - -
aNumbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were
resubmitted to up to two additional rounds. Data points that were still not filled after this procedure had been left blank.
bLogistic regression analysis values are adjusted for age.
cX2 and P-values for the deviation of observed and the numbers expected from the Hardy-Weinberg equilibrium (HWE) in the controls.
dAllele A2 carries the 16-bp insertion within intron 3.
OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0134463.t001
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and DFS (log-rank P = 0.04; P = 0.002 and P = 0.02, respectively) when compared with those
receiving hormonal or radiotherapy or with age lower than 60, respectively. No other clinico-
pathological parameters were associated with survival (after both univariate and multivariate
analysis).
Patients with homozygous variant genotype A2A2 of rs17878362 polymorphism were at
higher risk of relapse or metastasis (HR = 2.15, 95%CI 1.04–4.44, P = 0.04; Table 3). On the
other hand, patients carrying GC genotype of rs1042522 were at lower risk of relapse or metas-
tasis (HR = 0.66, 95%CI 0.44–1.00, P = 0.05). Concerning haplotype analyses, the haplotype
A1-C-C-G was associated with lower risk of relapse or metastasis (HR = 0.34, 95%CI 0.14–0.84,
P = 0.02; Table 4).
For significant associations, we have also applied the multivariate Cox regression analysis.
Patients with advanced age (>60 years old) and those not receiving any hormonal or radiother-
apy resulted in association with a shortened OS and DFS (S1 File). In the recessive model,
rs1042522 was still associated with lower risk of relapse or metastasis (HR = 0.65, 95%CI 0.44–
0.96, P = 0.03).
Adjuvant chemotherapy
In patients receiving only adjuvant chemotherapy, rs1042522 was significantly associated with
OS (log-rank for recessive model P = 0.02; Fig 1). In particular, when patients with the homo-
zygous GG genotype were compared to C allele carriers, they showed longer survival
(HR = 0.21, 95%CI 0.05–0.94, P = 0.04).
After stratification for anthracycline-based chemotherapy, rs17878362 was associated with
OS (log-rank P = 0.02). In particular, a better survival was observed for those patients carrying
Table 2. TP53 haplotype distribution between BC patients and controls.
Haplotypesa Controlsb Casesb ORc 95% CI P
n = 1222 n = 1410
dA1-G-C-G 775 898 REF
All others 437 394 0.78 0.65–0.93 0.006*
A2-C-C-G 153 179 1.06 0.82–1.37 0.67
A1-C-C-G 84 85 0.81 0.58–1.13 0.21
A1-C-T-G 65 95 1.36 0.96–1.93 0.09
A1-C-C-A 55 0 - - -
A2-G-C-G 50 24 0.36 0.21–0.61 0.0001*
A1-G-T-G 17 8 - - -
A1-G-C-A 9 0 - - -
A2-G-C-A 3 0 - - -
A2-C-C-A 1 0 - - -
A2-C-T-G 0 2 - - -
A2-G-T-G 0 1 - - -
aLoci rs17878362, rs1042522, rs12947788, rs17884306.
bNumber of alleles are reported. Because each individual has two alleles, the total number of alleles will be twice the total number of individuals.
Individuals with missing haplotype data were not included in the analyses.
cAdjusted for age.
dAllele A2 carries the 16-bp insertion within intron 3
OR, odds ratio; CI, confidence interval. Significant P-values are in bold.
doi:10.1371/journal.pone.0134463.t002
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the A1A2 genotype and undergoing anthracycline-based therapy (HR = 0.14, 95%CI 0.02–
1.00, P = 0.05; Table 5). In the same group of treated patients, rs1042522 polymorphism was
also associated with both OS and DFS (log-rank P = 0.02 and 0.007, respectively; Table 5).
Namely, we have observed a better survival for those patients carrying the GC genotype and
undergoing anthracycline-based chemotherapy (OS: HR = 0.31, 95%CI 0.11–0.90, P = 0.03;
DFS: HR = 0.34, 95%CI 0.15–0.77, P = 0.01 respectively). In a recessive model, the associations
remained the same (log-rank P = 0.01 and 0.01, respectively; Table 5).
The stratification for anthracycline-based chemotherapy or for taxane-based chemotherapy
did not show any significant associations of TP53 haplotype distribution with the OS or DFS
(data not shown).
Hormonal therapy
Among patients receiving only the hormonal therapy, rs17878362 polymorphism was
significantly associated with DFS (log-rank for recessive model P = 0.04; Fig 2). In particular,
we have observed a worse survival for those patients carrying the variant A2A2 genotype
(HR = 2.66, 95%CI 1.02–6.94, P = 0.05).
Further stratification for hormonal-based therapy and the regime containing either tamoxi-
fen or inhibitors of aromatases agents did not show any significant associations with BC prog-
nosis (data not shown).
Discussion
In the present study, we investigated the role of genetic variations within TP53 gene on BC risk
and its clinical outcomes in a population from the Czech Republic. Recent meta-analyses sug-
gested that polymorphisms in TP53 taken individually are not presumably risk factors for BC
[20,21]. Our data on single TP53 polymorphisms are in good agreement with the above
Table 3. Overall (OS) and disease-free (DFS) survival in relation to SNP distributions (Cox regression).
Genotype OS DFS
Cases Events HR 95% CI P Events HR 95%CI P
rs17878362
A1A1 470 52 REF - - 78 REF - -
A1A2 163 16 0.87 0.50–1.52 0.63 24 0.88 0.56–1.39 0.58
A2A2 24 3 1.07 0.33–3.43 0.91 8 2.15 1.04–4.44 0.04
A1A2+ A2A2 187 19 0.90 0.53–1.52 0.69 32 1.03 0.68–1.56 0.88
rs1042522
GG 369 44 REF - - 71 REF - -
GC 271 25 0.82 0.50–1.34 0.42 33 0.66 0.44–1.00 0.05
CC 55 4 0.62 0.22–1.71 0.35 9 0.88 0.44–1.75 0.71
GC+CC 326 29 0.78 0.49–1.25 0.30 42 0.70 0.48–1.02 0.06
rs12947788
CC 592 63 REF - - 97 REF - -
CT 99 11 1.06 0.56–2.00 0.87 16 1.00 0.59–1.70 0.99
TT 5 0 - - - 0 - - -
CT+TT 104 11 1.00 0.53–1.90 0.99 16 0.95 0.56–1.61 0.85
The SNP rs17884306 was monomorphic in cases, thus not presented.
HR, hazard ratio; 95% CI, confidence interval. Significant results in bold.
doi:10.1371/journal.pone.0134463.t003
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postulation. In contrast, there are also meta-analyses reporting that rs17878362 may contribute
to susceptibility of BC [22,38]. On the other hand, TP53 haplotypes have not been comprehen-
sively explored regarding the BC risk and prognosis.
Interestingly, in the case-control study we found that the TP53 A2-G-C-G haplotype was
associated with a decreased risk of BC when compared with the most common haplotype
A1-G-C-G. Globally, all the detected haplotypes were associated with decreased risk of the dis-
ease when compared with A1-G-C-G.
Although some studies found an association between sporadic BC and rs1042522,
rs17878362 or their respective haplotypes [39–41], the results are rather inconclusive due to
limited sample size (108, 159, 122 patients, respectively), differences in allele frequencies
between ethnic groups or staging of the malignancy.
In previous reports, we have observed a differential distribution of specific haplotypes
between cancer patients and controls, suggesting that prevalent haplotypes within TP53may
Table 4. OS and DFS in relation to haplotype distributions (Cox regression).
Haplotypea OS DFS
Casesb Eventsb HR 95%CI P Events HR 95%CI P
cA1-G-C-G 896 104 REF 157 REF
All others 390 36 0.81 0.55–1.18 0.26 59 0.88 0.65–1.19 0.40
A2-C-C-G 178 16 0.78 0.46–1.32 0.35 29 0.95 0.64–1.42 0.81
A1-C-T-G 92 10 0.97 0.50–1.85 0.91 15 0.96 0.57–1.64 0.89
A1-C-C-G 85 5 0.54 0.22–1.31 0.17 5 0.34 0.14–0.84 0.02*
aLoci rs17878362, rs1042522, rs12947788, rs17884306.
b Number of alleles are reported. Because each individual has two alleles, the total number of alleles is twice the total number of individuals. Individuals
with missing haplotype data were not included in the analyses.
cAllele A2 carries the 16-bp insertion within intron 3
HR, hazard ratio; 95% CI, confidence interval. Significant results in bold.
doi:10.1371/journal.pone.0134463.t004
Fig 1. Kaplan-Meier overall survival curves for TP53 rs1042522 polymorphism in patients receiving
only adjuvant chemotherapy (log-rank for recessive model P = 0.02).Numbers of patients at risk are
indicated in the lower part of the plot.
doi:10.1371/journal.pone.0134463.g001
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modulate both CRC and pancreatic cancer risk [27,28]. Interestingly, we have observed a simi-
lar pattern also for BC patients. The haplotypes within TP53 along with SNPs in other genes in
its pathway may impact the onset of pancreatic cancer and CRC, as well as BC. Thus, our
results seem to point to general mechanisms based on common genetic background involved
in the development of solid tumors. As previously observed for colorectal and pancreatic
Table 5. OS and DFS in relation to SNP distributions in patients treated with anthracycline-based chemotherapy (Cox regression).
Genotype OS DFS
Cases Events HR 95% CI P Events HR 95%CI P
rs17878362
A1A1 159 22 REF - - 35 REF - -
A1A2 53 1 0.14 0.02–1.00 0.05 5 0.42 0.16–1.06 0.07
A2A2 7 2 1.86 0.44–7.93 0.40 3 2.03 0.62–6.61 0.24
A1A2+ A2A2 60 3 0.35 0.11–1.18 0.09 8 0.60 0.28–1.28 0.19
rs1042522
GG 120 21 REF - - 33 REF - -
GC 82 4 0.31 0.11–0.90 0.03 7 0.34 0.15–0.77 0.01*
CC 20 1 0.29 0.04–2.15 0.23 4 0.73 0.26–2.07 0.56
GC+CC 102 5 0.30 0.11–0.80 0.02* 11 0.42 0.21–0.84 0.01*
rs12947788
CC 189 21 REF - - 34 REF - -
CT 33 5 1.44 0.54–3.82 0.47 10 2.00 0.98–4.00 0.06
TT 2 0 - - - 0 - - -
CT+TT 35 5 1.33 0.50–3.53 0.57 10 1.80 0.89–3.65 0.10
The SNP rs17884306 was monomorphic in cases, thus not presented.
HR, hazard ratio; 95% CI, confidence interval. Significant results in bold; significant differences after Dunn–Bonferroni correction (P<0.02) are marked with
an asterisk.
doi:10.1371/journal.pone.0134463.t005
Fig 2. Kaplan-Meier disease-free survival curves for TP53 rs17878362 polymorphism in patients
receiving only the hormonal therapy (log-rank for recessive model).Numbers of patients at risk are
indicated in the lower part of the plot.
doi:10.1371/journal.pone.0134463.g002
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malignancies, the different distribution of TP53 haplotypes also in BC cases and controls may
be due to a linkage of the disease to yet unknown functional polymorphism(s) within TP53 or
in some neighboring genes on 17p that could carry putative functional variant(s) linked to the
detected haplotypes. This argument is supported by predictions of such associations and the
existence of large haplotype blocks within the human genome [42]. On the other hand, there
are several studies in which deletion of 17p have been frequently observed in BC patients [43–
45]. The reversal of the modulation effect of TP53 polymorphisms within haplotypes may also
point to additional polymorphism(s) that cause differential cancer risk, either directly or
through interaction with environmental factors [27]. p53 interacts with numerous cellular pro-
teins, including those in the control of programmed cell death. Above molecular interactions
might contribute to its inhibitory role in the tumorigenesis. TP53 is frequently mutated in vari-
ous solid tumors, including colorectal, pancreatic and breast cancers, and these mutations
result in the absence or dysfunction of the p53 protein [46].
Another novel finding emerging from this study was that two individual SNPs in TP53
(rs1042522 and rs17878362) were associated with patient´s survival in a set of 705 BC cases. In
particular, patients with variant genotype A2A2 in rs17878362 were at higher risk of relapse or
metastasis. After stratification for anthracycline-based chemotherapy, rs17878362 was also
associated with OS. The association of SNPs with longer OS and DFS, particularly in relation
to the anthracycline–based chemotherapy, is of interest since it is in contrast to mutations in
this gene that are generally associated with a poor prognosis in BC patients [47,48]. Apart
from few studies [23,49–51], the effect of TP53 polymorphisms on patients survival has not
been studied in detail. The role of TP53 as a predictive biomarker for treatment response still
remains a matter of debate. Interestingly, [49] observed on a relatively large set of Finnish sam-
ples that patients carrying the homozygous variant CC genotype of rs1042522 had significantly
poorer survival than BC patients with other genotypes. A similar pattern of association was
also observed in the study of Toyama et al. (2007) on Japanese BC women, in the one on a Chi-
nese population [24] and more recently in the work of [26] on a Spanish group of BC. Interest-
ingly, patients with rs1042522 GC genotype were at lower risk of relapse or metastasis, as well
as those with the less frequent haplotype A1-C-C-G.
The association of rs17878362 to patient’s survival is of particular interest since the func-
tional relevance of rs17878362 is unknown. Intronic sequences in this gene have been impli-
cated in the regulation of gene expression and in DNA–protein interactions [52]. Rs17878362
may also be in linkage disequilibrium with other yet unidentified genes, thus explaining its
association with a distinctive phenotype.
The common G allele of rs1042522 is associated with a form of the p53 protein that is a
more potent inducer of apoptosis than the one containing the C allele [53]. It has been sug-
gested that patients carrying the GG genotype may respond more favorably to radiation or che-
motherapy [54]. For example, the higher efficiency of GG genotype in inducing apoptosis is
reflected in vivo in a better outcome in carriers of this genotype with advanced squamous head
and neck carcinoma, and receiving chemo-radiotherapy [55]. However, these effects of the G
allele may be reversed by a somatic p53 mutation on this allele [56]. Retention of the G allele
with loss of the C allele in the tumor tissue has been associated with reduced survival in GC
heterozygous BC patients [57].
It has been shown in various in vitro and mouse experiments that cell cycle arrest or apopto-
sis induced by radiotherapy and various chemotherapeutic drugs depends on an intact TP53
pathway [58,59]. Preclinical studies suggested p53-dependent anthracycline-induced apoptosis
and p53-independent taxane activity [58,60,61]. Other investigations have presented data in
support of reduced anthracycline activity in TP53mutated tumors [62,63]. Thus, the presence
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of variations in the TP53 gene could be one of the underlying causes of drug resistance, the
major cause of treatment failure and cancer death.
We are aware of certain limitations of this study, such as: i) the different age distribution
among cases and controls, ii) the non-homogenous proportion of patients with neoadjuvant
and adjuvant treatment, iii) the wide range of therapeutic agents used. BC risk is also tightly
linked to non-genetic factors such as pregnancy and hormonal history. Unfortunately, we were
not able to assemble this information. Other variables such as age at menarche, oophorectomy,
pregnancy and lactation history were also not included for comparison between cases and con-
trols, since they were not available for both groups. These limitations may be counterbalanced
by the homogeneity of the population and the detailed follow-up. To overcome the possible
effect of age, we have repeated the analyses selecting patients and controls by matching for ±5
years. After matching, 570 patients (median age 56 years, range 27–71) and 575 controls
(median age 51 years; range 33–91) were included in the analyses. For all the analyses per-
formed, we obtained similar results for both study groups (whole unmatched and matched
case-control group) (S1 File).
For the three studied polymorphisms, we also applied the Dunn-Bonferroni correction for
multiple comparisons. After correction, the new adjusted threshold of P-value significance is
0.02 for analyses of individual SNPs. The rs1042522 polymorphism still appeared to be an
independent prognostic marker in breast cancer patients.
In conclusion, in our study conducted on a Czech population of Caucasian origin, we
reported for the first time that the most frequent TP53 haplotype, previously associated with an
increased CRC and pancreatic cancer risks, was also associated with an increased BC suscepti-
bility. These results suggest that a particular genetic background based on certain haplotypes in
relevant genes such as TP53may play a role in the susceptibility of solid cancers, as demon-
strated on gastrointestinal cancers and BC. Importantly, we have also observed that both indi-
vidual polymorphisms or specific haplotypes of the TP53 gene were associated with BC clinical
outcome.
Further studies are needed to replicate these findings in independent and larger populations
to support the hypothesis that SNPs and haplotypes in TP53may be reliable predictive bio-
markers in solid tumors and may help in directing to a better pre-selection of patients accord-
ing to administered chemotherapeutic agents. Moreover, it is important to characterize
functional relevance of the identified genetic variants and to elucidate their biologic
associations.
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